Authors: Ong Thế Duệ1, Phùng Lâm Tới1, Đỗ Quỳnh Trang1, Đỗ Trà My1, Nguyễn Tuấn Việt1
1. 1.Health Strategy and Policy Institute - Ministry of Health.
Objective: To evaluate the cost-effectiveness of sequential treatment with first-line Afatinib versus Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam.
Methods: The decision tree model was built to estimate the cost-effectiveness of two treatment sequences, applying the payer's perspective. Clinical efficacy parameters are compiled from published clinical trials to estimate progression-free survival and treatment costs of each treatment line. Treatment cost parameters and adverse event management are collected based on clinical expert consultation.
Results: The sequential treatment with first-line Afatinib had a greater mean time on treatment than that of Osimertinib, at 29.2 months and 24.8 months, respectively. Compared to the sequential treatment with first-line Osimertinib, the sequential treatment with first-line Afatinib is cost-effective.
Conclusion: The sequentialt reatment with first-line Afatinib is cost-effective when compared to that of Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam.
Source: Vietnam Medical Journal
Doi: https://doi.org/10.51298/vmj.v527i2.5854